BridgeBio Pharma (NASDAQ:BBIO) Stock Purchase Reported by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

BridgeBio Pharma Stock Up 1.1%

BBIO stock opened at $79.54 on Thursday. BridgeBio Pharma, Inc. has a 52 week low of $62.50 and a 52 week high of $93.42. The company has a fifty day simple moving average of $69.89 and a two-hundred day simple moving average of $72.79. The firm has a market capitalization of $15.49 billion, a P/E ratio of -26.16 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.12. The company had revenue of $353.17 million during the quarter, compared to analysts’ expectations of $293.47 million. During the same quarter in the prior year, the business posted ($0.95) EPS. The company’s revenue was up 192.6% on a year-over-year basis. As a group, analysts anticipate that BridgeBio Pharma, Inc. will post -2.55 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Silvant Capital Management LLC bought a new position in shares of BridgeBio Pharma in the 2nd quarter worth $28,000. Allworth Financial LP purchased a new stake in shares of BridgeBio Pharma during the 2nd quarter worth $31,000. Root Financial Partners LLC bought a new stake in BridgeBio Pharma during the third quarter valued at about $28,000. SBI Securities Co. Ltd. boosted its position in BridgeBio Pharma by 55.3% during the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock valued at $29,000 after purchasing an additional 157 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in BridgeBio Pharma during the second quarter valued at about $44,000. Institutional investors own 99.85% of the company’s stock.

Insider Activity

In other BridgeBio Pharma news, CEO Neil Kumar sold 34,980 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $82.53, for a total transaction of $2,886,899.40. Following the completion of the sale, the chief executive officer directly owned 243,327 shares of the company’s stock, valued at approximately $20,081,777.31. This represents a 12.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the sale, the chief accounting officer owned 120,687 shares of the company’s stock, valued at approximately $8,792,047.95. This trade represents a 1.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 56,980 shares of company stock worth $4,563,699 in the last quarter. 14.23% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BBIO shares. UBS Group reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Friday, October 30th. TD Cowen decreased their price target on BridgeBio Pharma from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Canaccord Genuity Group raised their price target on BridgeBio Pharma from $106.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Mizuho raised their price target on BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 1st. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, October 5th. Nineteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.26.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.